NO773378L - Baerer for fremstilling av lagringsstabil poliovaksine - Google Patents

Baerer for fremstilling av lagringsstabil poliovaksine

Info

Publication number: NO773378L
Authority: NO; Norway
Prior art keywords: cystine; virus; tris; approximately; carrier
Prior art date: 1976-11-29

Application number

NO773378A

Other languages

English (en)

Norwegian (no)

Inventor

Adolf Von Seefred

Joong Hwan Chuun

Hildegarde M G Macmorine

Original Assignee

Connaught Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-11-29

Filing date

1977-10-04

Publication date

1978-05-30

1977-10-04 Application filed by Connaught Lab filed Critical Connaught Lab

1978-05-30 Publication of NO773378L publication Critical patent/NO773378L/no

Links

238000003860 storage Methods 0.000 title description 10
238000004519 manufacturing process Methods 0.000 title description 4
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 27
229960003067 cystine Drugs 0.000 description 26
241000991587 Enterovirus C Species 0.000 description 22
235000019393 L-cystine Nutrition 0.000 description 22
239000004158 L-cystine Substances 0.000 description 22
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 22
229960005486 vaccine Drugs 0.000 description 22
241000700605 Viruses Species 0.000 description 21
239000007983 Tris buffer Substances 0.000 description 17
230000000087 stabilizing effect Effects 0.000 description 12
239000002609 medium Substances 0.000 description 11
241000274177 Juniperus sabina Species 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
108010010803 Gelatin Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
229920000159 gelatin Polymers 0.000 description 8
239000008273 gelatin Substances 0.000 description 8
235000019322 gelatine Nutrition 0.000 description 8
235000011852 gelatine desserts Nutrition 0.000 description 8
239000000243 solution Substances 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
230000002779 inactivation Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229960001539 poliomyelitis vaccine Drugs 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000002970 Calcium lactobionate Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000709701 Human poliovirus 1 Species 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229940124867 Poliovirus vaccine Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229940050954 calcium lactobionate Drugs 0.000 description 1
235000019307 calcium lactobionate Nutrition 0.000 description 1
RHEMCSSAABKPLI-SQCCMBKESA-L calcium;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RHEMCSSAABKPLI-SQCCMBKESA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO773378A 1976-11-29 1977-10-04 Baerer for fremstilling av lagringsstabil poliovaksine NO773378L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA266,768A CA1067406A (en)	1976-11-29	1976-11-29	Stabilized oral poliovaccine and stabilizing medium therefor

Publications (1)

Publication Number	Publication Date
NO773378L true NO773378L (no)	1978-05-30

Family

ID=4107389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO773378A NO773378L (no)	1976-11-29	1977-10-04	Baerer for fremstilling av lagringsstabil poliovaksine

Country Status (10)

Country	Link
AT (1)	AT351161B (de)
BE (1)	BE861265A (de)
CA (1)	CA1067406A (de)
DE (2)	DE2747662A1 (de)
DK (1)	DK145175C (de)
FI (1)	FI57534C (de)
FR (1)	FR2371927A1 (de)
NL (1)	NL7713087A (de)
NO (1)	NO773378L (de)
SE (1)	SE426440B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4252792A (en)	1979-09-21	1981-02-24	Douglas Industries, Inc.	Injectable rabies vaccine composition and method for preparing same
EP0049296B1 (de) *	1980-10-02	1985-03-27	Schering Corporation	Injizierbare Tollwutimpfstoffzusammensetzung und Verfahren zu ihrer Herstellung
NL8102740A (nl) *	1981-06-05	1983-01-03	Nederlanden Staat	Virusvaccins en werkwijze ter bereiding daarvan.
US5360736A (en) *	1992-06-04	1994-11-01	Merck & Co., Inc.	Process for attenuated varicella zoster virus vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE665076A (de) *	1963-12-23	1965-12-08

1976
- 1976-11-29 CA CA266,768A patent/CA1067406A/en not_active Expired
1977
- 1977-10-04 NO NO773378A patent/NO773378L/no unknown
- 1977-10-11 FI FI773015A patent/FI57534C/fi not_active IP Right Cessation
- 1977-10-24 DE DE19772747662 patent/DE2747662A1/de active Pending
- 1977-11-03 SE SE7712473A patent/SE426440B/xx not_active IP Right Cessation
- 1977-11-25 DE DE2752725A patent/DE2752725C2/de not_active Expired
- 1977-11-28 AT AT850077A patent/AT351161B/de not_active IP Right Cessation
- 1977-11-28 BE BE182976A patent/BE861265A/xx not_active IP Right Cessation
- 1977-11-28 NL NL7713087A patent/NL7713087A/xx not_active Application Discontinuation
- 1977-11-28 DK DK526477A patent/DK145175C/da active
- 1977-11-29 FR FR7735923A patent/FR2371927A1/fr active Granted

Also Published As

Publication number	Publication date
DE2752725C2 (de)	1987-02-12
FR2371927B1 (de)	1981-06-19
DE2747662A1 (de)	1978-06-01
DK526477A (da)	1978-05-30
FI773015A7 (fi)	1978-05-30
FI57534B (fi)	1980-05-30
DK145175C (da)	1983-02-28
FR2371927A1 (en)	1978-06-23
SE426440B (sv)	1983-01-24
NL7713087A (nl)	1978-05-31
FI57534C (fi)	1980-09-10
CA1067406A (en)	1979-12-04
DE2752725A1 (de)	1978-06-15
ATA850077A (de)	1978-12-15
SE7712473L (sv)	1978-05-30
BE861265A (fr)	1978-03-16
DK145175B (da)	1982-09-27
AT351161B (de)	1979-07-10

Publication	Publication Date	Title
CA1333562C (en)	1994-12-20	Preservation of viruses
US6884422B1 (en)	2005-04-26	Freeze-dried hepatitis A attenuated live vaccine and its stabilizer
US6039958A (en)	2000-03-21	Stabilized live vaccine
Hopps et al.	1963	Biologic characteristics of a continuous kidney cell line derived from the African green monkey
JP6253161B2 (ja)	2017-12-27	乾燥された生物学的材料を安定化するための方法及び組成物
CA2065023A1 (en)	1991-02-16	Stabilized vaccine compositions
JPS6314729A (ja)	1988-01-21	生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン
NO773378L (no)	1978-05-30	Baerer for fremstilling av lagringsstabil poliovaksine
JPH06234659A (ja)	1994-08-23	安定化生ワクチン
CN113122510A (zh)	2021-07-16	一种传染性造血器官坏死病疫苗及其病毒在胖头鱥肌肉细胞上扩增的方法
US4057626A (en)	1977-11-08	Process for detoxifying influenza B virus
Fogel et al.	1969	Markers of rubella virus strains in RK13 cell culture
CN110893235A (zh)	2020-03-20	一种鲫造血器官坏死病灭活疫苗及其制备方法
MXPA05008695A (es)	2008-03-07	Estabilizacion de composiciones virales.
GB1564998A (en)	1980-04-16	Vaccine and stabilizing solution therefor
CN110093322A (zh)	2019-08-06	Mg132作为疫苗生产增效剂及稳定剂的应用
Webb et al.	2019	Argentine and Bolivian hemorrhagic fevers (South American hemorrhagic fevers)
Wagner	1954	Influenza Virus Infection of Transplanted Tumors: I. Multiplication of a “Neurotropic” Strain and Its Effect on Solid Neoplasms
Wolf et al.	1969	Infectious pancreatic necrosis virus: lyophilization and subsequent stability in storage at 4 C
US3836626A (en)	1974-09-17	Canine distemper virus vaccine
CA1038757A (en)	1978-09-19	Ethyleneimine inactivated organisms
Ozaki et al.	1963	Reaction of poliovirus and formaldehyde in magnesium chloride solution to enhance potency of killed-virus vaccine
Adams et al.	1972	Factors affecting the stability of transmissible enteritis virus of turkeys
Tyndall et al.	1963	l-Cystine requirement for production of Coxsackie B3 virus in cultured monkey heart cells
RU2129442C1 (ru)	1999-04-27	Способ получения вакцины против чумы плотоядных